• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALT alert in real time by email
    New Drug Application (NDA): 215935
    Company: CALLIDITAS THERAPEUTICS AB
    • Email

    Products on NDA 215935

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    TARPEYO BUDESONIDE 4MG CAPSULE, DELAYED RELEASE;ORAL Prescription TBD TBD No

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 215935

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    12/15/2021 ORIG-1 Approval Type 5 - New Formulation or New Manufacturer PRIORITY; Orphan

    Label is not available on this site.

    Therapeutic Equivalents for NDA 215935

    TARPEYO

    There are no Therapeutic Equivalents.

    Get the next $CALT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALT

    DatePrice TargetRatingAnalyst
    6/20/2023$60.00Buy
    H.C. Wainwright
    3/1/2023$18.00Neutral
    Guggenheim
    12/20/2021$52.00 → $62.00Buy
    HC Wainwright & Co.
    More analyst ratings